Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance
Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance
早前報道，HUTCHMED將收到來自武田的1000萬支付，因爲FRUZAQLA在歐洲爲轉移性結直腸癌實現了First National報銷。
US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe —
1000萬美元的里程碑付款給HUTCHMED，緊隨其後的是在歐洲的首次國家報銷——
— Follows June 2024 European approval of FRUZAQLA (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade —
—— 這標誌着2024年6月FRUZAQLA（fruquintinib）的歐洲批准，該藥物是十多年來歐盟首個針對轉移性結直腸癌的新型口服靶向治療，無論生物標誌物狀態如何——
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。